PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms

Abstract

Spontaneously hypertensive rat (SHR) is a suitable model for studies of the complications of hypertension. It is known that activation of poly(ADP-ribose) polymerase enzyme (PARP) plays an important role in the development of postinfarction as well as long-term hypertension induced heart failure. In this study, we examined whether PARP-inhibitor (L-2286) treatment could prevent the development of hypertensive cardiopathy in SHRs. 6-week-old SHR animals were treated with L-2286 (SHR-L group) or placebo (SHR-C group) for 24 weeks. Wistar-Kyoto rats were used as aged-matched, normotensive controls (WKY group). Echocardiography was performed, brain-derived natriuretic peptide (BNP) activity and blood pressure were determined at the end of the study. We detected the extent of fibrotic areas. The amount of heat-shock proteins (Hsps) and the phosphorylation state of Akt-1Ser473, glycogen synthase kinase (GSK)-3βSer9, forkhead transcription factor (FKHR)Ser256, mitogen activated protein kinases (MAPKs), and protein kinase C (PKC) isoenzymes were monitored. The elevated blood pressure in SHRs was not influenced by PARP-inhibitor treatment. Systolic left ventricular function and BNP activity did not differ among the three groups. L-2286 treatment decreased the marked left ventricular (LV) hypertrophy which was developed in SHRs. Interstitial collagen deposition was also decreased by L-2286 treatment. The phosphorylation of extracellular signal-regulated kinase (ERK)1/2Thr183-Tyr185, Akt-1Ser473, GSK-3βSer9, FKHRSer256, and PKC εSer729 and the level of Hsp90 were increased, while the activity of PKC α/βIIThr638/641, ζ/λ410/403 were mitigated by L-2286 administration. We could detect signs of LV hypertrophy without congestive heart failure in SHR groups. This alteration was prevented by PARP inhibition. Our results suggest that PARP-inhibitor treatment has protective effect already in the early stage of hypertensive myocardial remodeling.

Puerarin protects against CCl4-induced liver fibrosis in mice: possible role of PARP-1 inhibition

“…PARP-1 inhibition is announced to improve cardiac dysfunction and reduce inflammatory response and focal fibrosis in diabetic cardiomyopathy. [47,48] Deres L, et al even prevent the development of cardiac remodeling, which is characterized by interstitial fibrosis, with PARP-inhibitor [49]. In this paper, the administration of CCl 4 up-regulates hepatic PARP-1 expression, activates the NF-κB signaling pathway, generates more ROS and increases the permeability of the mitochondrial membrane which promotes cytochrome C released from intermembrane space to cytoplasm and leads to the activation of caspase 3 and apoptosis.…”

Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure

“…Plasma B-type natriuretic peptide-45 levels (BNP-45) were determined by enzyme immunoassay (BNP-45, Rat EIA Kit, Phoenix Pharmaceuticals Inc., CA, USA) [28]. …”

Insulin resistance and cognitive dysfunction

“…Tau protein phosphorylation is due to regulation of protein kinases and phosphatases, with glycogen synthase kinase-3 beta (GSK-3β) and mitogen-activated protein kinase inducing phosphorylation [77]. Neurofibrillary tangles play an important role in AD pathology, and they are mainly composed of hyperphosphorylated tau molecules [78,79].…”